MedTrace Logo

Rescue Therapy for Helicobacter Pylori Eradication Treatment

NCT04531059 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 368

Last updated 2024-12-30

No results posted yet for this study

Summary

Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. However, tetracycline is clinically unavailable in China and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy in which tetracycline was replaced by minocycline.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Esomeprazole

Proton pump inhibitor

DRUG

Bismuth Potassium Citrate

Gastric mucosal protective drug with anti-H. pylori effect

DRUG

Tetracycline,Metronidazole

Antibiotics for H. pylori eradication

DRUG

Minocycline,Metronidazole

Antibiotics for H. pylori eradication

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2022-12-20
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531059 on ClinicalTrials.gov